Ionis Pharmaceuticals Inc
IONS69.150USD
+0.750+1.10%
Fechamento 10/03, 16:00（ET）Cotações atrasadas em 15 min
11.01BValor de mercado
PerdaP/L TTM
Mais detalhes de Ionis Pharmaceuticals Inc Empresa
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Informações de Ionis Pharmaceuticals Inc
Código da empresaIONS
Nome da EmpresaIonis Pharmaceuticals Inc
Data de listagemMay 17, 1991
CEODr. Brett P. Monia, Ph.D.
Número de funcionários1069
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 17
Endereço2855 Gazelle Court
CidadeCARLSBAD
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92010
Telefone17609319200
Sitehttps://www.ionis.com/
Código da empresaIONS
Data de listagemMay 17, 1991
CEODr. Brett P. Monia, Ph.D.
Executivos da empresa Ionis Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
180.01K
--
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
79.66K
-11.15%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
57.13K
--
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
56.83K
+0.29%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
47.47K
--
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
37.42K
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
--
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
15.94K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
180.01K
--
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
79.66K
-11.15%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
57.13K
--
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
56.83K
+0.29%
Detalhamento da receita
Moeda: USDAtualizado em: ter, 4 de mar
Moeda: USDAtualizado em: ter, 4 de mar
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Distribuição de ações
Atualizado em: sáb, 23 de ago
Atualizado em: sáb, 23 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
14.83%
The Vanguard Group, Inc.
10.47%
T. Rowe Price Investment Management, Inc.
10.07%
Capital World Investors
7.87%
BlackRock Institutional Trust Company, N.A.
5.47%
Outro
51.29%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
14.83%
The Vanguard Group, Inc.
10.47%
T. Rowe Price Investment Management, Inc.
10.07%
Capital World Investors
7.87%
BlackRock Institutional Trust Company, N.A.
5.47%
Outro
51.29%
Tipos de investidores
Investidores
Proporção
Investment Advisor
70.88%
Investment Advisor/Hedge Fund
17.08%
Hedge Fund
16.01%
Research Firm
2.02%
Pension Fund
1.13%
Individual Investor
0.78%
Bank and Trust
0.68%
Sovereign Wealth Fund
0.28%
Family Office
0.02%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
790
172.50M
108.22%
-7.29M
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
2023Q2
770
142.08M
99.29%
+364.04K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
23.64M
14.83%
+29.41K
+0.12%
Jun 30, 2025
The Vanguard Group, Inc.
16.68M
10.47%
+329.29K
+2.01%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
16.05M
10.07%
-126.81K
-0.78%
Jun 30, 2025
Capital World Investors
12.54M
7.87%
+178.19K
+1.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.73M
5.47%
-171.64K
-1.93%
Jun 30, 2025
Bellevue Asset Management AG
7.85M
4.93%
--
--
Jun 30, 2025
Wellington Management Company, LLP
6.35M
3.98%
-2.07M
-24.60%
Jun 30, 2025
Deep Track Capital LP
4.89M
3.07%
+327.34K
+7.17%
Jun 30, 2025
State Street Global Advisors (US)
4.53M
2.84%
-314.74K
-6.50%
Jun 30, 2025
Two Sigma Investments, LP
4.46M
2.8%
+678.11K
+17.95%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Nome
Proporção
iShares Russell 3000 ETF
0%
iShares Russell 1000 Value ETF
0%
Fidelity MSCI Health Care Index ETF
0%
VanEck Morningstar SMID Moat ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
JPMorgan BetaBuilders US Mid Cap Equity ETF
0%
iShares Russell 2500 ETF
0%
iShares US Small-Cap Equity Factor ETF
0%
Schwab U.S. Broad Market ETF
0%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0%
Ver Mais
iShares Russell 3000 ETF
Proporção0%
iShares Russell 1000 Value ETF
Proporção0%
Fidelity MSCI Health Care Index ETF
Proporção0%
VanEck Morningstar SMID Moat ETF
Proporção0%
Fidelity Nasdaq Composite Index ETF
Proporção0%
JPMorgan BetaBuilders US Mid Cap Equity ETF
Proporção0%
iShares Russell 2500 ETF
Proporção0%
iShares US Small-Cap Equity Factor ETF
Proporção0%
Schwab U.S. Broad Market ETF
Proporção0%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
